FAQ
What does Pharming do?
Pharming develops innovative products for the safe, effective treatment of rare diseases and unmet medical needs. We are specialists in the production of protein therapeutics. Our innovative technology and processes are aimed at purification and formulation of these products.
What is HAE?
Hereditary Angioedema (HAE) is a rare genetic condition which occurs in approximately 1 in 30,000 people worldwide. Symptoms include episodes of swelling in the hands, feet, abdomen, face and airway. Patients may suffer bouts of excruciating abdominal pain, nausea and vomiting that is exacerbated by swelling in the intestinal wall. Airway (laryngeal) swelling is particularly dangerous and can lead to death by asphyxiation.
What causes an HAE attack?
C1 inhibitor is normally found in our blood. Patients with HAE, however, have low levels of functioning C1 inhibitor. There are many triggers for an attack including stress, medications, trauma, hormone changes etc. An attack begins with the activation of (FXII and Kallikrein) that are normally kept in check by C1 inhibitor (C1-INH). Eventually, because there is not enough C1-INH available, this activation leads to the production of bradykinin, which leads to fluid leaking out of the blood vessels and into the tissues (angioedema).
What is Recombinant technology?
Recombinant technology is a state of the art, efficient way to produce complex human proteins such as C1-INH without the need for human plasma donations. This technology has been used for more than 30 years to make medicines that treat a wide variety of conditions such as asthma, diabetes, hemophilia, and cancer.
What is RUCONEST?
Ruconest (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in the US, Israel, all 28 EU countries plus Norway, Iceland and Liechtenstein.
Can you explain the mode of action of RUCONEST?
RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor (rhC1INH). C1 esterase inhibitor (C1INH) is a protein that naturally occurs in the human body. It belongs to the class of serine-protease inhibitors or serpins. It regulates several inflammatory pathways in the body by inhibiting certain proteins (proteases) that are part of the human immune system. Deficiency of functional C1 inhibitor leads to excessive activation of the complement system and other immunological and haemostatic pathways, giving cause to angioedema attacks.
General/Corporate
Where is Pharming's corporate headquarters?
Pharming Group NV
Darwinweg 24
2333 CR Leiden
The Netherlands
Darwinweg 24
2333 CR Leiden
The Netherlands
Where is the company incorporated?
In the Netherlands
When did Pharming go public? What was the price?
Pharming’s shares are listed on Euronext Amsterdam since 1999. The opening share price was 0,883366
How is Pharming stock traded?
Pharming’s shares are listed on Euronext Amsterdam Under the symbol PHARM, since 1999. The shares (ISIN Code: NL0010391025) are only traded through the book-entry facilities of Euroclear Nederland.
Company Inquiries
How many employees does Pharming have?
Pharming currently has over 260 employees.
Where can I find out more about Pharming Group N.V.?
You can find all information about Pharming via www.pharming.com
Should you have any questions, please contact investor@pharming.com
Where can I get the latest corporate news releases and financial reports?
You can find the latest press releases here; https://www.pharming.com/news
You can find all financial reports here; https://www.pharming.com/investors/financial-documents
How can I view documents Pharming Group N.V. has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?
You can find the SEC filings here
Who makes up the Pharming Group Executive Management team and Board of Directors?
To learn more about our Executive Committee and our Board of Directors please click here.
How can I obtain further information or materials on Pharming Group
Should you have any further questions please don’t hesitate to contact us at investor@pharming.com
When is your next earnings release scheduled? How can I receive email updates for this information?
Please sign up to our distribution list on our website to receive our press releases in your inbox; www.pharming.com/contact
Whom should I contact regarding investor inquiries?
You can send an e-mail to investor@pharming.com
What Analysts track Pharming at this current time?
The following analysts track Pharming:
Oppenheimer & Co. Inc.
H.C. Wainwright
Stifel Financial Corp.
First Berlin Research
ROTH Capital Partners
Van Leeuwenhoeck
Kempen Healthcare
Portzamparc
Annual Meeting
How can obtain a copy of your annual report and proxy?
You can find all information regarding our shareholder meetings on the page ‘Events & Presentations’
When and where will Pharming’s hold its next annual meeting?
The next shareholder meeting, the AGM, will take place on the 19th of May 2021. You can find all our events on the Pharming website.